spacer
home > ebr > winter 2002 > truncate rna preparation in crna labelling reactions without sacrificing microarray performance?
PUBLICATIONS
European Biopharmaceutical Review

Truncate RNA Preparation in cRNA Labelling Reactions Without Sacrificing Microarray Performance?

When preparing cRNA samples for microarray analysis, researchers must choose between mRNA and total RNA as the starting material for labelling. The method of choice for high quality mRNA preparation typically involves total RNA extraction followed by an additional step of mRNA purification. While this method generally yields high quality substrates for microarray target preparation, its major drawback is the addition of an extra step to the preparation process which increases the amount of product lost by approximately 30% and also increases the potential for sample degradation, both of which result in lower amplified cRNA yields and decreased microarray sensitivity. In light of these issues, microarray researchers have recently developed protocols to improve the feasibility of using total RNA directly in the labelling reaction.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Jenny Xiao, Applications Scientist at Agilent Technologies Dr Jenny Xiao obtained her PhD in Molecular Genetics at the University of Hawaii in 1997. Her dissertation focused on gene cloning, differential gene expression and the characterisation of the molecular basis for white-eye mutation in the Oriental fruit fly.
Subsequently, Jenny became a postdoctoral fellow at Stanford University, using microarray to perform apoptosis studies that identified redox and mitochondrial elements which control resistance or sensitivity to cell death. She is currently an Applications Scientist at Agilent Technologies, working on its gene expression solutions platform.

spacer
Dr Jenny Xiao
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Surge of Indian biosimilars market forecast in 2019

16th April 2019: New data from CPhI shows that, despite ongoing reputational challenges, India’s biologics market is set for robust growth in 2019 driven by biosimilars production. The India specific findings from CPhI’s bio league tables predict strong ‘bio growth potential’ in India throughout 2019 in the build-up to the 13th edition of CPhI India 2019, which will take place at the India Expo Centre in Delhi NCR.
More info >>

White Papers

Overcoming research challenges with Adaptive Trials

PCI Pharma Services

There has been cause for concern within the pharmaceutical industry over the last five years, regarding increasing research and development costs, combined with a fall in the number of new drugs brought to market. In an attempt to overcome this issue there has been a significant rise in the use of adaptive clinical trial designs, whilst saving time and money as well as facilitating more effective decision making. One of the biggest challenges that pharmaceutical companies have experienced has been delivering compliant clinical trials supplies across diverse patient populations in the relatively short timeframes that adaptive trial designs require, remaining focused on ensuring that patient compliance and product quality is in no way compromised. This demand has led to the launch of fast response services that support Research and Development in responding to changing dosing regimens mid-trial.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: it’s where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on today’s hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement